Вакцина Sinopharm CNBG проти COVID-19 (Ukrainian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Вакцина Sinopharm CNBG проти COVID-19" in Ukrainian language version.

refsWebsite

Global rank Ukrainian rank

4^th place

5^th place

765^th place

2,518^th place

309^th place

1,954^th place

low place

18^th place

74^th place

2^nd place

4^th place

doi.org

Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, Kang Y, Su JG, Zhang J, Yang T, Hussein S, ElDein MS, Yang SS, Lei W, Gao XJ, Jiang Z, Cong X, Tan Y, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Hou JW, Lei ZH, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM (червень 2022). Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nature Communications. 13 (1): 3654. Bibcode:2022NatCo..13.3654K. doi:10.1038/s41467-022-31379-0. PMC 9237056. PMID 35760812. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)

Emergency use of Sinopharm's new CNBG protein vaccine approved in UAE. Gulf News. 27 грудня 2021. Процитовано 27 грудня 2021. (англ.)

Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, Kang Y, Su JG, Zhang J, Yang T, Hussein S, ElDein MS, Yang SS, Lei W, Gao XJ, Jiang Z, Cong X, Tan Y, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Hou JW, Lei ZH, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM (червень 2022). Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nature Communications. 13 (1): 3654. Bibcode:2022NatCo..13.3654K. doi:10.1038/s41467-022-31379-0. PMC 9237056. PMID 35760812. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)

Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, Kang Y, Su JG, Zhang J, Yang T, Hussein S, ElDein MS, Yang SS, Lei W, Gao XJ, Jiang Z, Cong X, Tan Y, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Hou JW, Lei ZH, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM (червень 2022). Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nature Communications. 13 (1): 3654. Bibcode:2022NatCo..13.3654K. doi:10.1038/s41467-022-31379-0. PMC 9237056. PMID 35760812. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)

Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, Kang Y, Su JG, Zhang J, Yang T, Hussein S, ElDein MS, Yang SS, Lei W, Gao XJ, Jiang Z, Cong X, Tan Y, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Hou JW, Lei ZH, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM (червень 2022). Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial. Nature Communications. 13 (1): 3654. Bibcode:2022NatCo..13.3654K. doi:10.1038/s41467-022-31379-0. PMC 9237056. PMID 35760812. {{cite journal}}: Недійсний |display-authors=6 (довідка) (англ.)

China's new recombinant COVID-19 vaccine starts human tests. Xinhua. 25 квітня 2021. Процитовано 5 травня 2021. (англ.)